Patents by Inventor Niksa Kastrapeli

Niksa Kastrapeli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TARGETING COMPLEMENT FACTOR D AND USES THEROF
    Publication number: 20240034779
    Abstract: Antibodies that specifically bind to complement factor D in a pH sensitive manner, are described, as well as methods of making and using such antibodies.
    Type: Application
    Filed: October 6, 2023
    Publication date: February 1, 2024
    Inventors: Sebastien Vallee, Madhusudan Natarajan, Rizwana Islam, Muthuraman Meiyappan, Angela Norton, Niksa Kastrapeli, Christophe Blanchetot, Christophe Steyaert
  • BISPECIFIC ANTIBODIES AGAINST PLASMA KALLIKREIN AND FACTOR XII
    Publication number: 20230117565
    Abstract: Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.
    Type: Application
    Filed: June 13, 2022
    Publication date: April 20, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Stephen R. Comeau, Andrew Nixon, Niksa Kastrapeli, Jon A. Kenniston, Gregory P. Conley, Shauna Mason, Allison P. Lindberg, Kristopher Kopacz, Burt Adelman
  • Bispecific antibodies against plasma kallikrein and Factor XII
    Patent number: 11390687
    Abstract: Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: July 19, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen R. Comeau, Andrew Nixon, Niksa Kastrapeli, Jon A. Kenniston, Gregory P. Conley, Shauna Mason, Allison P. Lindberg, Kristopher Kopacz, Burt Adelman
  • BISPECIFIC ANTIBODIES AGAINST PLASMA KALLIKREIN AND FACTOR XII
    Publication number: 20180118851
    Abstract: Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis. One aspect of the present disclosure is a bispecific antibody, comprising: a first polypeptide that comprises a light chain of a first antibody, the light chain comprising a light chain variable region (VL) and a light chain constant region (CL) (e.g., a kappa light chain or a lambda light chain); and a second polypeptide that comprises a heavy chain of the first antibody, the heavy chain comprising a heavy chain variable region (VH) and a heavy chain constant region (CH).
    Type: Application
    Filed: December 31, 2015
    Publication date: May 3, 2018
    Applicant: Dyax Corp.
    Inventors: Stephen R. Comeau, Andrew Nixon, Niksa Kastrapeli, Jon A. Kenniston, Gregory P. Conley, Shauna Mason, Allison P. Lindberg, Kristopher Kopacz, Burt Adelman